Anavex Life Sciences Corp.
AVXL- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001314052
No open-market purchases or sales by Anavex Life Sciences Corp. insiders were filed in the last 90 days; 180 institutions reported holding it in 13F filings for Q2 2026, worth $95.9M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −8 vs. previous quarter
- 180
- 13F valueReported value at the end of Q2 2026
- $95.9M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding AVXL, Q2 2026
No superinvestor reported holding AVXL at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Anavex Life Sciences Corp. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 17, 2024 (view filing) | Jun 14 | 3 days | Donhauser Peter D.O.Director | PPurchase | +2.83K | $3.64 | +$10.3K | +130.9%5.00K after | |
| May 17, 2024 (view filing) | May 15 | 2 days | Thomas SteffenDirector | PPurchase | +5.00K | $4.52 | +$22.6K | New position5.00K after | |
| Apr 1, 2024 (view filing) | Mar 28 | 4 days | Missling Christopher UPresident and CEO | SSale | −73.4K | $5.11 | −$375.0K | −5.5%1.25M after | |
| Jun 30, 2023 (view filing) | Jun 28 | 2 days | Missling Christopher UPresident and CEO | SSale | −268.0K | $7.98 | −$2.14M | −20.8%1.02M after | |
| May 27, 2022 (view filing) | May 25 | 2 days | Skarpelos AthanasiosDirector | SSale | −50.0K | $9.06 | −$453.0K | −3.7%1.31M after | |
| Jul 1, 2021 (view filing) | Jun 29 | 2 days | Missling Christopher UPresident and CEO | SSale | −51.6K | $26.00 | −$1.34M | −4.8%1.02M after | |
| Jul 1, 2021 (view filing) | Jun 29 | 2 days | Boenisch SandraPFO and Treasurer | SSale | −166.7K | $26.53 | −$4.42M | −87.9%23.0K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Anavex Life Sciences Corp. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 8,055,628 | $20.9M | 0.00% | +446,010+5.9% | Added |
| Vanguard Capital Management LLC | 4,054,589 | $10.5M | 0.00% | +190,639+4.9% | Added |
| Two Sigma Investments, LP | 3,046,538 | $7.89M | 0.01% | −201,350−6.2% | Reduced |
| Geode Capital Management, LLC | 2,407,473 | $6.24M | 0.00% | +219,198+10.0% | Added |
| State Street Corp | 1,922,770 | $4.98M | 0.00% | −2,589,258−57.4% | Reduced |
| Federated Hermes, Inc. | 1,071,809 | $2.78M | 0.00% | +539,557+101.4% | Added |
| AQR Capital Management LLC | 963,014 | $2.49M | 0.00% | +206,222+27.2% | Added |
| Vanguard Portfolio Management LLC | 948,633 | $2.46M | 0.00% | +165,485+21.1% | Added |
| Summit Financial, LLC | 909,430 | $2.36M | 0.03% | −31,025−3.3% | Reduced |
| Goldman Sachs Group Inc | 890,634 | $2.31M | 0.00% | +86,199+10.7% | Added |